Navigation Links
Avaxia Biologics Announces Appointment of Michael D. Rivard as VP Corporate Development
Date:6/12/2012

LEXINGTON, Mass., June 12, 2012 /PRNewswire/ -- Avaxia Biologics, Inc., a privately-held biotechnology company developing oral antibody drugs, announced today that Michael D. Rivard has joined the company as Vice President, Corporate Development.

Mr. Rivard has over 20 years of experience in the biotechnology industry and has held senior management positions in corporate development at ArQule, Inc., Synta Pharmaceuticals Corp., Galenea Corp., and VaxDesign Corporation.  Mr. Rivard also served as Associate Counsel (Intellectual Property) at the University of Massachusetts and as an Associate Attorney at the law firm of Palmer & Dodge (now Edwards Wildman Palmer LLP).  Mr. Rivard earned a Juris Doctor degree from the UCLA School of Law and a BA degree in biochemistry from Bowdoin College.

"I am thrilled to join this exciting company," said Mr. Rivard.  "The AVX Oral Antibody™ technology makes the gastrointestinal (GI) tract accessible to potent and safe antibody therapy.  Potential applications for our antibodies include inflammatory bowel disease (IBD), oral mucositis, GI acute radiation syndrome, celiac disease, diabetes, and any other disease which involves an antigen, soluble protein, or receptor in the GI tract or oral cavity.  The breadth of the platform offers many opportunities to work with collaborators in the pharmaceutical industry as we develop our lead product for IBD."

Barbara S. Fox, CEO of Avaxia, added, "Mike brings to Avaxia a unique mix of knowledge and experience in corporate development, intellectual property, and corporate law, as well as a scientific background.  We are confident that Mike will lead us successfully in achieving our goals of partnering our AVX-470 oral anti-TNF antibody and finding collaborators who share our vision of developing oral antibodies for other exciting targets in the GI tract."

About Avaxia Biologics, Inc.: Avaxia Biologics is developing orally administered antibody therapeutics that act locally within the gastrointestinal (GI) tract.  Antibodies are widely used as therapeutics and have nearly $50 billion in annual sales worldwide.  Ordinary antibodies are not administered orally because they are destroyed in the GI tract.  In contrast, Avaxia has developed proprietary antibodies that are stable in the GI tract.  AVX Oral Antibodies™ make disease targets in the GI tract readily accessible to antibody therapeutics.  Avaxia is developing products for inflammatory bowel disease, GI acute radiation syndrome, celiac disease, oral mucositis, diabetes, and obesity.


'/>"/>
SOURCE Avaxia Biologics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Avaxia Biologics is Awarded U.S. Patent for Method to Treat Radiation Damage to the Digestive Tract and Mucositis Caused by Radiation
2. Althea Technologies Appoints Dr. Kristin DeFife, Director, Biologics Manufacturing And Jack Wright, VP, Sales and Marketing
3. Synthetic Biologics Appoints Carol Reed, M.D., as Senior Vice President of Clinical & Regulatory Affairs
4. CSL Behring Announces FDA Filing of Biologics License Application for 4-Factor PCC for Urgent Reversal of Vitamin K Antagonist Anticoagulant Therapy
5. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
6. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012
7. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
8. Misonix Announces New Distribution Agreement For Panama
9. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
10. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
11. Boston Scientific Announces CE Mark and European Launch of Emerge™ PTCA Dilatation Catheter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... , Jan. 20, 2017  Ethicon Endo-Surgery, ... Megadyne Medical Products, Inc., a privately held ... markets electrosurgical tools used in operating rooms ... of Ethicon,s* advanced energy devices with Megadyne,s ... major step forward in Ethicon,s goal to ...
(Date:1/20/2017)... VAE, January 20, 2017 ... Bedarf an Nothilfe   Die internationale humanitäre Stadt ... Hilfsgüter zu schaffen   Seine Hoheit ... der VAE sowie Herrscher von Dubai ... Stadt der Hilfe (International Humanitarian City IHC) zu verdreifachen, ...
(Date:1/19/2017)... YORK , Jan. 19, 2017 The ... provides understanding and access to partnering deals and agreements ... - Trends in partnering deals - Top deals by ... stage of development, technology type The report provides ... entered into by the world,s leading healthcare companies. ...
Breaking Medicine Technology:
(Date:1/21/2017)... , ... January 21, 2017 , ... Seamild, the largest ... the futuristic vision of its owner and founder. As Oat is recognized globally as ... everybody he knows personally as he believes it is a move to sow the ...
(Date:1/21/2017)... ... 21, 2017 , ... In the United States, 20 million women and 10 ... they often feel shame for having struggled with an eating disorder as well as ... “Rising Strong in Life After an Eating Disorder” -- to be featured at this ...
(Date:1/20/2017)... (PRWEB) , ... January 20, 2017 , ... Source Vitál ... and 100 percent pure essential oils, announced the company had a successful visit to ... The annual ECRM event gives companies that work in the nutritional, sports and health ...
(Date:1/20/2017)... ... January 20, 2017 , ... International Protein, a company based out ... announced it attended the January ECRM trade show in Hilton Head, SC. , ... was determined to create a line of products that would elevate her fitness regime. ...
(Date:1/20/2017)... ... ... “The Angel”: a heartwarming and earnest tale of faith and believing ... “The Angel” is the creation of published author, Marjorie Lund-Fontaine, a former professional violinist, ... , When asked of her new book, Marjorie says, “‘The Angel’ was written as ...
Breaking Medicine News(10 mins):